Compare Stocks

→ How Biden has already won 2024 (From Porter & Company) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMV IMV		$0.66	$0.48 ▼ $12.70	$9.63M	0.95	233,607 shs	44,800 shs
PFNX Pfenex	$12.75	$0.00	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMV IMV	0.00%	0.00%	0.00%	0.00%	0.00%

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMV IMV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMV IMV	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMV IMV	$330K	0.00	N/A	N/A	($0.69) per share	0.00
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMV IMV	-$37.99M	-$4.59	N/A	N/A	N/A	-11,547.42%	-12,695.41%	-104.84%	N/A
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMV IMV	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMV IMV	N/A	2.93	2.93
PFNX Pfenex	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
IMV IMV	15.37%
PFNX Pfenex	N/A

Insider Ownership

Company	Insider Ownership
IMV IMV	0.33%
PFNX Pfenex	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
IMV IMV	97	11.71 million	11.67 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable

PFNX and IMV Headlines

Source	Headline
	NKY Medical Holdings Ltd Class A 300109 morningstar.com - January 31 at 6:39 PM
	Last available seats at PFS West Coast Conference next week pharmaphorum.com - May 19 at 6:04 PM
	Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks news.google.com - May 4 at 7:30 PM
	150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal news.google.com - April 13 at 12:19 AM
	Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq news.google.com - April 6 at 5:35 PM
	LENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal news.google.com - March 29 at 1:06 PM
	Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal news.google.com - March 17 at 10:21 AM
	Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire news.google.com - March 15 at 8:24 PM
	San Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune news.google.com - March 15 at 8:24 PM
	Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal news.google.com - March 13 at 7:40 AM
	Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR news.google.com - March 1 at 11:39 AM
	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian news.google.com - February 23 at 5:24 PM
	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire news.google.com - February 22 at 5:46 PM
	Biosimilar Growth Hormones Global Market Report 2023 - Yahoo Finance news.google.com - February 8 at 4:13 PM
	Biosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo Finance news.google.com - February 8 at 4:13 PM
	Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal news.google.com - February 7 at 3:49 AM
	Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com news.google.com - January 27 at 9:00 PM
	Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal news.google.com - January 27 at 9:34 AM
	Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR news.google.com - January 6 at 1:28 PM
	Abzena Names Matthew Stober CEO - Contract Pharma news.google.com - January 5 at 2:36 PM
	Abzena hires Matthew Stober to lead the company through the next ... - Bio-IT World news.google.com - January 4 at 5:54 PM
	Osteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 \| Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal news.google.com - December 7 at 8:29 AM
	Ligand Reports Third Quarter 2022 Financial Results - StreetInsider.com news.google.com - November 8 at 4:47 AM
	Krystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking Alpha news.google.com - November 6 at 2:43 AM

Company Descriptions

IMV

NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Pfenex

NYSEAMERICAN:PFNX

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial